Avicanna: Science-Based, Low-Cost, Impressive Pedigree, Global Ambitions

Mark Bunting, president and publisher of Capital Ideas Media, sits down with Aras Azadian, CEO, Chairman and Co-Founder of newly-public Avicanna (TSX:AVCN). This is a biopharmaceutical company focused on science and evidence-based delivery that has partnerships with several large hospitals such as Princess Margaret, and pharmaceutical giant Johnson & Johnson. Azadian explains Avicanna’s low-cost cultivation in Colombia and its four verticals structure in agriculture, medical, consumer and pharma. He also discusses how the company does things the right way, and why its setting gold standards as it scales up into a global leader.